LT3335708T - Įvedimas gama hidroksibutirato su monokarboksilato transporteriais - Google Patents

Įvedimas gama hidroksibutirato su monokarboksilato transporteriais

Info

Publication number
LT3335708T
LT3335708T LTEP17200764.3T LT17200764T LT3335708T LT 3335708 T LT3335708 T LT 3335708T LT 17200764 T LT17200764 T LT 17200764T LT 3335708 T LT3335708 T LT 3335708T
Authority
LT
Lithuania
Prior art keywords
hydroxybutirate
monocarboxylate
gama
conveyors
introduction
Prior art date
Application number
LTEP17200764.3T
Other languages
English (en)
Inventor
Mark Eller
Original Assignee
Jazz Pharmaceuticals Ireland Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51031733&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3335708(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jazz Pharmaceuticals Ireland Limited filed Critical Jazz Pharmaceuticals Ireland Limited
Publication of LT3335708T publication Critical patent/LT3335708T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medical Informatics (AREA)
  • Primary Health Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Toxicology (AREA)
LTEP17200764.3T 2013-03-01 2014-02-28 Įvedimas gama hidroksibutirato su monokarboksilato transporteriais LT3335708T (lt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361771557P 2013-03-01 2013-03-01
US201361777873P 2013-03-12 2013-03-12
US13/837,714 US9050302B2 (en) 2013-03-01 2013-03-15 Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
US13/873,000 US8952029B2 (en) 2013-03-01 2013-04-29 Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
US13/872,997 US8772306B1 (en) 2013-03-01 2013-04-29 Method of administration of gamma hydroxybutyrate with monocarboxylate transporters

Publications (1)

Publication Number Publication Date
LT3335708T true LT3335708T (lt) 2020-05-11

Family

ID=51031733

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP17200764.3T LT3335708T (lt) 2013-03-01 2014-02-28 Įvedimas gama hidroksibutirato su monokarboksilato transporteriais

Country Status (21)

Country Link
US (10) US9050302B2 (lt)
EP (3) EP3335708B1 (lt)
JP (1) JP6433440B2 (lt)
KR (1) KR102239042B1 (lt)
CN (2) CN111317730A (lt)
AU (1) AU2014223373B2 (lt)
BR (1) BR112015021012A8 (lt)
CA (1) CA2902948C (lt)
CY (2) CY1120086T1 (lt)
DK (2) DK2961399T3 (lt)
ES (2) ES2775779T3 (lt)
HR (1) HRP20200215T1 (lt)
IL (1) IL240874B (lt)
LT (1) LT3335708T (lt)
MX (1) MX387339B (lt)
PL (2) PL2961399T3 (lt)
PT (2) PT2961399T (lt)
SG (1) SG11201505029QA (lt)
SI (1) SI3335708T1 (lt)
TW (1) TWI619492B (lt)
WO (1) WO2014134380A1 (lt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
EP2540725A1 (de) 2006-05-04 2013-01-02 Boehringer Ingelheim International GmbH Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
BRPI0916997A2 (pt) * 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
CA2794171C (en) 2010-03-24 2018-07-03 Jazz Pharmaceuticals, Inc. Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
CN102946875A (zh) 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
US8591922B1 (en) 2012-12-14 2013-11-26 Jazz Pharmacuticals, Inc. Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
CA2999367C (en) 2015-09-23 2023-09-26 Xw Laboratories Inc. Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合
US11000498B2 (en) 2016-07-22 2021-05-11 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
ES2970887T3 (es) 2016-09-06 2024-05-31 Axsome Malta Ltd Forma de solvato de carbamato de (R)-2-amino-3-fenilpropilo
EP4316592A3 (en) 2016-10-06 2024-05-01 Axsome Malta Ltd. Carbamoyl phenylalaninol compounds and uses thereof
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
AU2018278332B2 (en) 2017-06-02 2022-05-19 Jazz Pharmaceuticals Ireland Limited Methods and compositions for treating excessive sleepiness
KR102643275B1 (ko) 2017-07-31 2024-03-04 재즈 파마슈티칼즈 아일랜드 리미티드 카바모일 페닐알라니놀 유사체 및 이의 용도
JP2020533415A (ja) * 2017-09-12 2020-11-19 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． ナルコレプシーの処置におけるガボキサドールの使用
CA3115122A1 (en) 2018-11-19 2020-05-28 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
EP3930702A1 (en) 2019-03-01 2022-01-05 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
MX2021016006A (es) * 2019-06-28 2022-04-07 Univ Copenhagen Tratamiento de trastornos del sistema nervioso central (snc) con perturbaciones del sueño.
TW202135790A (zh) 2019-12-24 2021-10-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 Ghb給藥
TW202139986A (zh) * 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
WO2021209956A1 (en) 2020-04-16 2021-10-21 Flamel Ireland Limited Methods of administering gamma-hydroxybutyrate compositions with divalproex sodium
US20220040128A1 (en) * 2020-04-16 2022-02-10 Flamel Ireland Limited Methods of administering gamma-hydroxybutyrate compositions with divalproex sodium
CN115038432B (zh) 2020-06-18 2023-12-26 凯瑞康宁生物工程（武汉）有限公司 水溶性活性药物成分的控制释放制粒
WO2022020621A1 (en) 2020-07-24 2022-01-27 XWPharma Ltd. Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative
EP4225274A1 (en) 2020-10-05 2023-08-16 XWPharma Ltd. Modified release compositions of a gamma-hydroxybutyric acid derivative
WO2022076824A1 (en) 2020-10-08 2022-04-14 Jazz Pharmaceuticals Ireland Limited Sodium oxybate to treat idiopathic hypersomnia
EP4228620A2 (en) 2020-10-16 2023-08-23 Jazz Pharmaceuticals Ireland Limited Treatment methods using ghb
JP2024511991A (ja) 2021-03-19 2024-03-18 エックスダブリューファーマ リミテッド ガンマ－ヒドロキシ酪酸誘導体の組み合わされた放出製剤の薬物動態
WO2023062018A1 (en) 2021-10-11 2023-04-20 Jazz Pharmaceuticals Ireland Limited Method of administering oxybate
US20250073191A1 (en) 2022-01-11 2025-03-06 Jazz Pharmaceuticals Ireland Limited Method of administering oxybate
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
JP2026513019A (ja) 2023-02-03 2026-04-22 トリス・フアルマ・インコーポレーテツド １晩１回の低ナトリウムオキシベート組成物
EP4719375A1 (en) 2023-05-30 2026-04-08 Axsome Therapeutics, Inc. Solriamfetol for treating cognitive impairment in a subject with impaired cognition associated with obstructive sleep apnea and excessive daytime sleepiness
KR20260033050A (ko) 2023-06-29 2026-03-10 액섬 테라퓨틱스, 인크. 수유 여성에게 솔리암페톨을 투여하는 방법

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE237309C (lt)
US797171A (en) 1904-08-04 1905-08-15 Antonio Cerruti Fruit-washer.
GB922029A (en) 1960-05-19 1963-03-27 Equilibre Biolog L Therapeutic composition
US3051619A (en) 1960-05-19 1962-08-28 Equilibre Biolog L 4-hydroxy butyric acid therapeutic compositions and process of use for clinical sedation, hypnosis, or anaesthesia
GB971700A (en) 1961-02-02 1964-09-30 Boots Pure Drug Co Ltd Anti-Inflammatory Agents
FR2442M (fr) 1962-10-17 1964-04-06 Henry Eugene L'acide dipropylacétique et ses dérivés en tant que nouveuax médicaments dépresseurs du systeme nerveux central.
FR2383920A1 (fr) 1977-03-15 1978-10-13 Labaz Procede de preparation d'un derive d'acetonitrile et derive obtenu par ce procede
US4155929A (en) 1977-05-25 1979-05-22 Labaz Process for the preparation of an acetonitrile derivative
EP0044801B1 (de) 1980-07-17 1984-02-15 Josef Dr. Klosa Nichthygroskopische Salze der 4-Hydroxybuttersäure, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung pharmazeutischer Mittel
JPS61186319A (ja) * 1985-02-12 1986-08-20 Res Dev Corp Of Japan 睡眠覚醒調節剤
DD237309A1 (de) 1985-05-15 1986-07-09 Berlin Chemie Veb Verfahren zur herstellung eines lagerstabilen natriumsalzes der gamma-hydroxybuttersaeure
IT1217783B (it) 1988-06-03 1990-03-30 Farmaceutico Ct S R L Lab Impiego di salo dell,acido gamma idrossi butirrico per la preparazione di composizioni farmaceutiche adatta ad essereimpiegate nella terapia dell,alcolismo e composizioni relative
US4983612A (en) 1989-10-05 1991-01-08 American Home Products Corporation Antihypertensive benzopyran derivatives
DE4113984C2 (de) 1991-04-29 2002-05-08 Koehler Chemie Dr Franz Salze der 4-Hydroxy-Buttersäure
IT1271403B (it) 1993-03-26 1997-05-28 Ct Lab Farm Srl Sali dell'acido gamma-idrossibutirrico ad attivita' ansiolitica e per il trattamento degli stati depressivi
US5833599A (en) 1993-12-13 1998-11-10 Multum Information Services Providing patient-specific drug information
US5762955A (en) 1994-02-04 1998-06-09 Smith; Stephen Jay Method for application and maintenance of medication on body tissue
US7072840B1 (en) 1994-10-28 2006-07-04 Cybear, L.L.C. Prescription management system
US5845255A (en) 1994-10-28 1998-12-01 Advanced Health Med-E-Systems Corporation Prescription management system
US5758095A (en) 1995-02-24 1998-05-26 Albaum; David Interactive medication ordering system
US6112182A (en) 1996-01-16 2000-08-29 Healthcare Computer Corporation Method and apparatus for integrated management of pharmaceutical and healthcare services
US5990162A (en) 1997-08-29 1999-11-23 Orphan Medical, Inc. Method for treatment of fibromyalgia and chronic fatigue syndrome
US6014631A (en) 1998-04-02 2000-01-11 Merck-Medco Managed Care, Llc Computer implemented patient medication review system and process for the managed care, health care and/or pharmacy industry
CA2355293C (en) 1998-12-23 2005-08-16 Orphan Medical, Inc. Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
US6067524A (en) 1999-01-07 2000-05-23 Catalina Marketing International, Inc. Method and system for automatically generating advisory information for pharmacy patients along with normally transmitted data
US6204245B1 (en) * 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants
US6383764B1 (en) * 2000-04-28 2002-05-07 The Regents Of The University Of California Methods of identifying compounds for controlling absence seizures in a mammal relating to prolactin-releasing peptide(PrRP)
ES2383673T3 (es) 2000-09-22 2012-06-25 Jpi Commercial, Llc Composiciones de gamma-hidroxibutirato que contienen portadores de hidrato de carbonos
US6315720B1 (en) * 2000-10-23 2001-11-13 Celgene Corporation Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US7668730B2 (en) 2002-12-17 2010-02-23 JPI Commercial, LLC. Sensitive drug distribution system and method
RU2232012C1 (ru) 2003-06-02 2004-07-10 Иркутский государственный медицинский университет Способ лечения бруксизма
US20110237664A1 (en) * 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
KR20070085838A (ko) 2004-11-10 2007-08-27 더 트러스티이스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 운동 장애의 치료 방법
US20110145018A1 (en) * 2005-03-21 2011-06-16 Fotsch Edward J Drug and medical device safety and support information reporting system, processing device and method
US20080293698A1 (en) * 2005-05-16 2008-11-27 Joseph Johnson Methods and Compositions for Treating Arg
WO2010039861A2 (en) 2008-09-30 2010-04-08 The Regents Of The University Of Michigan Dendrimer conjugates
US8771735B2 (en) 2008-11-04 2014-07-08 Jazz Pharmaceuticals, Inc. Immediate release dosage forms of sodium oxybate
FR2938431B1 (fr) * 2008-11-14 2013-12-20 Debregeas Et Associes Pharma Nouvelle composition a base d'acide gamma-hydroxybutyrique
CA2794171C (en) 2010-03-24 2018-07-03 Jazz Pharmaceuticals, Inc. Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
EP2566462B1 (en) * 2010-05-04 2020-07-08 Jazz Pharmaceuticals Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
JP2013540748A (ja) 2010-09-16 2013-11-07 コーネル ユニバーシティー 血液脳関門の透過性を調節するためのアデノシン受容体シグナル伝達の使用法
US8591922B1 (en) 2012-12-14 2013-11-26 Jazz Pharmacuticals, Inc. Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters

Also Published As

Publication number Publication date
US20220193015A1 (en) 2022-06-23
KR20150125943A (ko) 2015-11-10
TW201511752A (zh) 2015-04-01
JP2016510031A (ja) 2016-04-04
EP3335708B1 (en) 2019-12-11
JP6433440B2 (ja) 2018-12-05
US11253494B2 (en) 2022-02-22
IL240874B (en) 2019-06-30
US20180200210A1 (en) 2018-07-19
US20140249222A1 (en) 2014-09-04
US8952029B2 (en) 2015-02-10
CA2902948C (en) 2019-12-31
HK1215539A1 (en) 2016-09-02
HRP20200215T1 (hr) 2020-05-15
US20160015662A1 (en) 2016-01-21
WO2014134380A1 (en) 2014-09-04
AU2014223373B2 (en) 2018-12-06
BR112015021012A2 (pt) 2017-07-18
US10213400B2 (en) 2019-02-26
CY1122992T1 (el) 2021-10-29
DK3335708T3 (da) 2020-02-24
CN111317730A (zh) 2020-06-23
MX387339B (es) 2025-03-18
ES2659284T3 (es) 2018-03-14
DK2961399T3 (en) 2018-02-19
US20190274980A1 (en) 2019-09-12
US9050302B2 (en) 2015-06-09
US9486426B2 (en) 2016-11-08
AU2014223373A1 (en) 2015-08-20
US11986446B2 (en) 2024-05-21
IL240874A0 (en) 2015-10-29
BR112015021012A8 (pt) 2019-11-26
KR102239042B1 (ko) 2021-04-12
EP2961399B1 (en) 2017-11-15
US10864181B2 (en) 2020-12-15
CY1120086T1 (el) 2018-12-12
PL2961399T3 (pl) 2018-05-30
PT3335708T (pt) 2020-03-17
CN105073106A (zh) 2015-11-18
TWI619492B (zh) 2018-04-01
US20140249115A1 (en) 2014-09-04
HK1256965A1 (en) 2019-10-04
PL3335708T3 (pl) 2020-08-24
EP3695833A1 (en) 2020-08-19
US20210128502A1 (en) 2021-05-06
EP3335708A1 (en) 2018-06-20
US20170049731A1 (en) 2017-02-23
US20210212970A1 (en) 2021-07-15
US8772306B1 (en) 2014-07-08
SG11201505029QA (en) 2015-07-30
SI3335708T1 (sl) 2020-04-30
EP2961399A1 (en) 2016-01-06
ES2775779T3 (es) 2020-07-28
CA2902948A1 (en) 2014-09-04
MX2015011242A (es) 2016-05-31
PT2961399T (pt) 2018-02-21

Similar Documents

Publication Publication Date Title
LT3335708T (lt) Įvedimas gama hidroksibutirato su monokarboksilato transporteriais
IL269045A (en) Aptamers and uses thereof
BR112015019373A2 (pt) processamento e transformação de biomassa
BR112016008141A2 (pt) Artigo
DK3003039T3 (da) Methyl/fluor-pyridinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser og fluor-pyrimidinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser
HRP20170840T1 (hr) Supstituirani ksantini i metode njihove uporabe
DOS2013000297S (es) Brazalete
DK3272997T3 (da) Choker
DK3063144T3 (da) Antiparasitære og pesticid-isoxazolinforbindelser
EP2979854A4 (en) ITEMS
PT2953948T (pt) Antagonistas de integrina fluorada
PL3030519T3 (pl) Trójpierścieniowe związki benzoksaborolu i ich zastosowania
IL243728A0 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
DK2943561T3 (da) Fotobioreaktor
PL2914261T3 (pl) Śmiertelność syntetyczna i leczenie nowotworu
EP2945942A4 (en) Voriconazole IMMUNOASSAY
BR112016003017A2 (pt) Estrutura de suporte e transportador
HUE039948T2 (hu) Csökkent oxidációjú készítmények
BR112015024661A2 (pt) silo e silo elevado
BR112015020275A2 (pt) estrutura flutuante
EP2970860A4 (en) Genetically modified bacteria
TH1401007376A (th) ไดอะซาสไปโรไซโคลแอลเคนและอะซาสไปโรไซโคลแอลเคนชนิดใหม่
ES1098808Y (es) Juguete-instrumento de muneco bailarin
ES1096036Y (es) Estructura alimentaria multidivisional
TH1401006815A (th) เส้นบะหมี่ที่ถูกแช่เยือกแข็ง และ วิธีการผลิตนั้น